AstraZeneca launches its new diabetes drug Onglyza



AstraZeneca diabetes drug cuts heart risks in major study

  • AstraZeneca's diabetes drug Farxiga showed heart-protecting benefits in a major clinical study.
  • Patients taking the drug had reductions in hospitalization for heart failure and cardiovascular-related deaths compared to those on placebo.
  • Complete study results will be presented at the annual meeting of the American Heart Association on Nov 10.

LONDON (Reuters) - AstraZeneca said on Monday its diabetes drug Farxiga met a key goal in a major clinical study designed to show the heart-protecting benefits of the medicine.

Diabetics are at increased risk of heart problems, making the cardiovascular (CV) profile of medicines to treat the condition a key focus for doctors and patients.

In the 17,000-patient trial known as Declare, patients on Farxiga achieved a statistically-significant and clinically-important reduction in hospitalization for heart failure or CV death compared with those on placebo, the company said.

There were also fewer major adverse cardiovascular events, although in this case the difference did not reach statistical significance.

Full results from the Declare study will be presented on Nov. 10 at the annual meeting of the American Heart Association.

Farxiga competes with rival diabetes drugs such as Eli Lilly's Jardiance and Novo Nordisk's Victoza, which has already shown certain heart benefits.






Video: AstraZeneca agrees .7bn deal for US biotech firm ZS Pharma

AstraZeneca diabetes drug cuts heart risks in major study
AstraZeneca diabetes drug cuts heart risks in major study images

2019 year
2019 year - AstraZeneca diabetes drug cuts heart risks in major study pictures

AstraZeneca diabetes drug cuts heart risks in major study recommend
AstraZeneca diabetes drug cuts heart risks in major study forecast photo

AstraZeneca diabetes drug cuts heart risks in major study photo
AstraZeneca diabetes drug cuts heart risks in major study pics

AstraZeneca diabetes drug cuts heart risks in major study AstraZeneca diabetes drug cuts heart risks in major study new pictures
AstraZeneca diabetes drug cuts heart risks in major study new picture

photo AstraZeneca diabetes drug cuts heart risks in major study
picture AstraZeneca diabetes drug cuts heart risks in major study

Watch AstraZeneca diabetes drug cuts heart risks in major study video
Watch AstraZeneca diabetes drug cuts heart risks in major study video

Communication on this topic: AstraZeneca diabetes drug cuts heart risks in , astrazeneca-diabetes-drug-cuts-heart-risks-in/
Communication on this topic: AstraZeneca diabetes drug cuts heart risks in , astrazeneca-diabetes-drug-cuts-heart-risks-in/ , astrazeneca-diabetes-drug-cuts-heart-risks-in/

Related News


5 Best Places for the Perfect Yoga Retreat
15 Coconut Oil Beauty Products to Celebrate World CoconutDay
Keto Krate Is The Snack Box Subscription You Didnt Know You Needed
Rheumatoid Arthritis: Treatment Transforms a Teacher and Triathlete
Want: The Perfect Broken-In Vintage Levi’s Denim Jacket (We FoundIt)
John McCain, Senator and Former Presidential Candidate, Dies at 81 After Fight Against Brain Cancer
How to handle the heat of the world’s hottest chilli
Finding Your Feet: 5 Things You Need To Know About Joanna Lumley’s New Film
10 Things No One Ever Tells You About: Whitening YourTeeth
Hand Raised Pork Pie Recipe
I Had A Heart Attack At Age 35—Just One Week After Having A Baby



Date: 12.12.2018, 21:07 / Views: 63541